A pre-clinical biotechnology company developing a new drug for pancreatic dancer. Our technology was developed by the Houchen lab at OUHSC.
COARE Biotechnology is focused on treating pancreatic cancer by targeting cancer stem cells (CSCs), the cells responsible for early cancer growth and metastasis. COARE has used its initial funding to develop a therapeutic monoclonal antibody (drug) that blocks the function of a key cancer promoting protein. We are currently in the pre-clinical phase of drug development and intend to perform all of the studies required for IND.